Available online on http://www.ijcpr.com/

International Journal of Current Pharmaceutical Review and Research 2023; 15(10): 42-48

Original Research Article

Assessing Serum Sodium Levels in Chronic Liver Disease (CLD) Patients and Determining the Association with the Severity and Outcome of Disease: An Observational Comparative Study

Ashraf Azam¹, Vinyanand Jha²

¹Senior Resident, Department of General Medicine, Darbhanga Medical College and Hospital, Darbhanga, Bihar, India

²Associate Professor, Department of General Medicine, Darbhanga Medical College and Hospital, Darbhanga, Bihar, India

Received: 01-04-2023 Revised: 17-05-2023 / Accepted: 23-06-2023 Corresponding author: Dr. Vinyanand jha Conflict of interest: Nil

Abstract

Aim: This study was done to study the serum sodium levels in chronic liver disease (CLD) patients and establish its association with the severity of disease in such patients.

Material & Methods: An observational cross-sectional study with 200 cases of chronic liver disease was done in the Department of General Medicine for 2 years.

Results: All patients had abdominal distension. It was observed that patients from group A had jaundice (p<0.05) and altered sensorium (p<0.001) significantly more commonly as compared to those from group B and C. Alcohol consumption was reported by 88.5% of the patients. Serum sodium levels were not significantly associated with alcohol consumption. Among all examination findings, icterus (p<0.05) and clubbing (p<0.01) were found to be significantly more common among patients from group A, as compared to patients from group B or C. Pallor, pedal edema, signs of liver cell failure and organomegaly were not significantly associated with serum sodium levels in our study population. Portal hypertension was observed in 85.5%, hepatic encephalopathy in 23.5%, hepatorenal syndrome in 21.5%, spontaneous bacterial peritonitis in 4.5% and coagulopathy in 18%. Of these, hepatic encephalopathy (p<0.01), hepatorenal syndrome (p<0.01) and coagulopathy (p<0.01) were found to occur significantly more common among patients from group A, as compared to those in patients from group B or C. We observed that mean direct bilirubin, alanine transaminase, aspartate transaminase and alkaline phosphatase were significantly higher among group A patients as compared to those with group B and group C. We also observed that mean Child Pugh score was significantly higher among group A patients as compared to those with group B and group C.

Conclusion: Patients with lower serum salt levels had a substantially higher MELD score and CPS. Low blood sodium levels were linked to more severe liver disease, greater complications, and increased death. As a result, we urge that serum salt levels be checked on a frequent basis in patients with chronic liver disease.

Keywords: Cirrhosis, Sodium, Hyponatremia, MELD, Prognosis.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Dysnatremia is the most common electrolyte disorder in hospitalized patients. It encompasses hyponatremic and hypernatremic conditions. It is a common finding at Intensive Care Unit (ICU) admission. [1-3] Nearly one third of critically ill patients have dysnatremia at ICU admission [2]. Hyponatremia is a pathologic condition defined as a serum sodium < 135 mmol/L. It is the most common electrolyte disorder in hospitalized patients. Up to 40% of the overall hospitalized patients have a hyponatremia at admission. [4]

Presence of severe hyponatremia on hospital admission has been demonstrated to be independently associated with an increased risk for ICU admission and poor prognosis. [5] Hyponatremia may be due to chronic organ dysfunctions (that is heart failure or liver dysfunction), diuretic use, syndrome of inappropriate antidiuretic hormone (ADH) secretion, adrenal insufficiency, and cerebral or renal salt wasting syndromes. Hyponatremia is often a marker of severity of underlying disease. [6,7] In addition to critical illness per se, factors contributing to hyponatremia in ICU include excess use of hypotonic fluids and drugs stimulating antidiuretic hormone secretion. [8] Hyponatremia is common in patients with advanced stages of liver diseases. Patients with chronic liver disease (CLD) may develop hyponatremia due to either hypovolemia or hypervolemia. Hyponatremia in CLD is currently defined with a level of serum sodium less than 130 meq/L. [9] Studies have shown that the severity of the hyponatremia is related to the severity of the chronic liver disease. [10-12]

Chronic liver disorders (CLD) are a major source of morbidity and death globally. Multiple etiological causes contribute to a similar clinicopathological pathophysiology in Chronic liver disorders, albeit progression rates and clinical course may differ. [13] The majority of the rise in CLD mortality has been documented from Asia and Africa's poor and low-middle income (LMIC) burden nations. Disease is changing demographically and epidemiologically in LMIC. India is one of the epicentres of this transformation. [14] Reduced serum sodium concentration is a common finding in patients with cirrhosis, being the most common electrolyte disorder in this setting. [9] Indeed, around 20% of patients had levels less than 130 mmol/l, the current criterion of hyponatremia in cirrhosis. Although hyponatremia can be seen in individuals with early or moderately severe cirrhosis from Child-Pugh classifications A and B, it is more common in people with advanced disease (Child-Pugh class C). The link between hyponatremia and cirrhosis severity is further supported by its close association with the occurrence of complications: the prevalence of hepatic encephalopathy, hepatorenal syndrome, and spontaneous bacterial peritonitis is significantly higher in patients with serum sodium concentrations of 130 mmol/l than in those with higher levels. In a study conducted in a government medical college in south Kerala, hyponatremia occurred in 57 percenatges of hospitalized patients with cirrhosis. [15]

Thus, the current study was conducted to investigate blood sodium levels in chronic liver disease patients and determine their relationship with the disease severity in such patients.

Material & Methods

An observational cross-sectional study with 200 cases of chronic liver disease was done in the Department of General Medicine, Darbhanga Medical College and Hospital, Darbhanga, Bihar, India for 2 years.

Inclusion Criteria:

Patients in the age group of 18 to 65 years, irrespective of gender, diagnosed with chronic liver disease.

Exclusion Criteria:

Patients aged less than 18 years, with comorbid cardiac failure, with comorbid chronic kidney disease and those taking drugs that alter serum sodium levels.

100 cases were divided into 3 groups: - Those with serum sodium levels less than or equal to 130 meq/l were classified as **group A**, those with serum sodium levels between 131-135 meq/l as **group B** and those with serum sodium levels greater than or equal to 136 meq/l as **group C**. In the present study, 100 patients were included. It was observed that 30% were in group A (\leq 130 mEq/l, n=30), 30% were in group B (131 to 135 mEq/l, n=30) and 40% were in group C (\geq 136 mEq/l, n=40).

Demographic information about the patients was obtained from their medical records. A history, biochemical markers, physical examination, gastrointestinal ultrasonography, and upper endoscopy were used to identify cirrhosis. Each patient's venous blood was taken and submitted to the institutional laboratory for analysis of serum electrolytes, liver function tests (LFTs), renal parameters, prothrombin time (PT), activated thromboplastin partial time (aPTT), and international normalised ratio (INR). An automatic biochemical analyzer was used to test the biochemical indicators, while an automated haematology analyzer was used to measure the whole blood cell counts. Complications in the patients included hepatic encephalopathy, varices, hepatorenal syndrome, and infections. In addition, child-Turcotte Pugh score (CPS) and model for end stage liver disease (MELD) score was calculated for all patients. [16]

Statistical analysis

All analysis were done using SPSS software, version 24.0. Descriptive analysis of quantitative parameters was expressed as means and standard deviation. Ordinal data were expressed as absolute number and percentage. Cross tables were generated and chi square test was used for testing of associations. One-way ANOVA was used for comparison of quantitative parameters, along with Bonferroni post-hoc test. A p value of <0.05 is considered statistically significant.

Results

Variables		Group A (≤ 130mEq/l, n=50)	Group B (131 to 135 mEq/l, n=50)	Group C (≥ 136mEq/l, n=100)	Total	P value
Age group (Years	s)		,	, ,		
25 to 40	N	10	16	30	56	
	%	20	32	30	28	
41 to 60	Ν	32	27	62	121	0.44
	%	64	54	62	60.5	
61 to 80	Ν	8	7	8	23	
	%	16	14	8	11.5	
Gender						
Female	Ν	6	9	30	45	
	%	12	18	30	22.5	0.22
Male	Ν	44	41	70	155	
	%	88	82	70	77.5	
Clinical presentati	on			•		
Abd distension	Ν	50	50	100	200	NA
	%	100	100	100	100	
GI bleed	Ν	10	10	16	36	0.15
	%	20	20	16	18	
Jaundice	Ν	26	16	20	62	< 0.05
	%	52	32	20	31	
Alt sensorium	Ν	29	10	8	47	< 0.001
	%	58	20	8	23.5	
	N	46	45	86	177	0.80
Alcohol	%	92	90	86	88.5	
Examination findi	ngs					
Pallor	N	10	10	20	40	0.88
	%	20	20	20	20	
Icterus	N	40	25	12	77	< 0.05
	%	80	50	12	38.5	
Clubbing	Ν	40	20	10	70	< 0.01
	%	40	40	10	35	
Pedal edema	N	45	40	75	160	0.75
	%	90	80	75	80	
S/o liver cell failure	N	45	48	90	183	0.16
	%	90	96	90	91.5	
Organomegaly	N	5	16	20	41	0.20
	%	10	32	20	20.5	0.20

Table 1: Comparison of baseline characteristics between groups based on serum sodium levels

All patients had abdominal distension. It was observed that patients from group A had jaundice (p<0.05) and altered sensorium (p<0.001)significantly more commonly as compared to those from group B and C. Alcohol consumption was reported by 88.5% of the patients. Serum sodium levels were not significantly associated with alcohol consumption. Among all examination findings, icterus (p<0.05) and clubbing (p<0.01) were found to be significantly more common among patients from group A, as compared to patients from group B or C. Pallor, pedal edema, signs of liver cell failure and organomegaly were not significantly associated with serum sodium levels in our study population.

Complications		Group A (≤ 130 mEq/l, n=50)	Group B (131 to135 mEq/l, n=50)	Group C (≥ 136mEq/l, n=100)	Total	P value*
Port hypertension	Ν	45	45	81	171	0.10
	%	90	90	81	85.5	
Hepatic	Ν	26	10	11	47	< 0.01
encephalopathy	%	52	20	11	23.5	
Hepatorenal	Ν	23	8	12	43	< 0.01
syndrome	%	46	16	12	21.5	
Spontaneous	Ν	6	3	0	9	0.55
bacterial peritonitis	%	12	6	0	4.5	
Coagulopathy	Ν	20	8	8	36	< 0.01
	%	40	16	8	18	

 Table 2: Comparison of complication rate between groups based on serum sodium levels

Portal hypertension was observed in 85.5%, hepatic encephalopathy in 23.5%, hepatorenal syndrome in 21.5%, spontaneous bacterial peritonitis in 4.5% and coagulopathy in 18%. Of these, hepatic encephalopathy (p<0.01), hepatorenal syndrome (p<0.01) and coagulopathy (p<0.01) were found to occur significantly more common among patients from group A, as compared to those in patients from group B or C.

Liver function		Mean	SD	Minimum	Maximum	P value*
Total bilirubin	Group A	3.14	2.34	0.50	9.40	
(mg/dl)	Group B	2.90	2.20	0.60	12.18	0.08
	Group C	2.20	1.80	0.61	7.13	
Direct bilirubin	Group A	2.10	1.80	0.21	6.20	
(mg/dl)	Group B	1.60	1.40	0.34	6.70	< 0.01
	Group C	1.30	1.20	0.30	4.45	
Alanine	Group A	86.34	84.16	11.19	545.15	
transaminase (U/l)	Group B	55.25	18.40	17.13	95.15	< 0.01
	Group C	45.90	16.90	12.15	82.12	
Aspartate	Group A	102.98	95.40	20.14	600.15	
transaminase (U/l)	Group B	66.64	20.80	30.15	149.13	< 0.01
	Group C	58.52	22.20	18.12	130.12	
Alkaline	Group A	140.60	96.06	80.12	624.10	
phosphatase(U/l)	Group B	100.80	29.00	70.15	192.19	< 0.01
	Group C	92.18	19.21	66.14	140.12	
Total protein	Group A	6.24	0.90	4.90	7.70	
(gm/dl)	Group B	6.20	0.70	4.20	8.56	0.80
	Group C	6.26	0.92	4.20	8.28	
	Group A	3.48	0.83	1.80	6.08	
Albumin (gm/dl)	Group B	3.30	0.72	1.91	5.15	0.09
	Group C	3.60	0.60	2.45	4.96	

 Table 3: Comparison of liver function between groups based on serum sodium levels

We observed that mean direct bilirubin, alanine transaminase, aspartate transaminase and alkaline phosphatase were significantly higher among group A patients as compared to those from group B or C respectively.

Table 4: Comparison of liver cirrhosis severity between groups based on serum sodium levels							
Variables	Mean	SD Minimum		Maximum	P value*		
MELD							
Group A	18.82	6.40	6.14	32.04			
Group B	14.56	5.55	8.13	30.02	< 0.01		
Group C	12.98	4.40	8.12	26.04			
CPS					·		
Group A	9.90	2.20	6.12	14.06			
Group B	8.82	1.60	6.12	13.07	< 0.01		
Group C	7.70	1.75	6.12	15.05			

 Table 4: Comparison of liver cirrhosis severity between groups based on serum sodium levels

We observed that mean MELD score was significantly higher among group A patients as compared to those with group B and group C. We also observed that mean Child Pugh score was significantly higher among group A patients as compared to those with group B and group C.

Outcome		Group A (≤ 130mEq/l, n=50)	Group B (131 to 135 mEq/l, n=50)	Group C (≥ 136mEq/l, n=100)	Total	P value*
Discharged	Ν	24	27	40	91	
	%	80	90	100	91	< 0.001
Expired	Ν	6	3	0	9	
	%	20	10	0	9	

Table 5: Comparison of mortality rate between groups based on serum sodium levels

Overall, 9 of the patients expired. It was observed that mortality was 20 percentages among group A patients, which was significantly higher than that of group B patients (10%) or group C patients (0%).

Discussion

Dysnatremia is an umbrella term to describe hypo or hypernatremia. Hyponatremia (serum sodium concentration <135 meq/L) and hypernatremia (serum sodium concentration >135mEq/L) both primarily are manifestations of imbalance of body water homeostasis which is dependent upon salt and water intake, insensible losses and urinary concentration or dilution (in most circumstances mediated by vasopressin). [17,18] Hyponatremia may be due to chronic organ dysfunctions (that is heart failure or liver dysfunction), diuretic use, syndrome of inappropriate antidiuretic hormone (ADH) secretion, adrenal insufficiency, and cerebral or renal salt wasting syndromes. Hyponatremia is often a marker of severity of underlying disease. [19,20] Hyponatremia affected 60% of the individuals in this research. Elkady et al observed that 43.5% had blood sodium levels of 125 mEq/l or less, whereas the rest had serum sodium levels greater than 125 mEq/l. [21] Kim and colleagues discovered that 27.1% of participants had serum sodium of 130 mmol/l, 20.8% had serum sodium of 131 to 135 mmol/l, and 52.1 percent had serum sodium of 136 mmol/l. [22] Umemura et colleagues studied mortality in cirrhotic patients on conventional diuretics and discovered links between blood sodium levels and clinical features. [23]

All patients had abdominal distension. It was observed that patients from group A had jaundice (p<0.05) and altered sensorium (p<0.001)significantly more commonly as compared to those from group B and C. Alcohol consumption was reported by 88.5% of the patients. Serum sodium levels were not significantly associated with alcohol consumption. Among all examination findings, icterus (p<0.05) and clubbing (p<0.01)were found to be significantly more common among patients from group A, as compared to patients from group B or C. Pallor, pedal edema,

signs of liver cell failure and organomegaly were not significantly associated with serum sodium levels in our study population. Portal hypertension was observed in 85.5%, hepatic encephalopathy in 23.5%, hepatorenal syndrome in 21.5%, spontaneous bacterial peritonitis in 4.5% and coagulopathy in 18%. Of these, hepatic encephalopathy (p<0.01), hepatorenal syndrome (p<0.01) and coagulopathy (p<0.01) were found to occur significantly more common among patients from group A, as compared to those in patients from group B or C. In another study, Elkady et al [21] found that 91% of individuals with blood sodium levels less than 125 mEq/l had hepatic encephalopathy, and 50% had upper gastrointestinal haemorrhage, which was considerably higher than those with serum sodium levels greater than 125 mEq/l. Ascites were shown to be considerably less prevalent in individuals with blood sodium levels of 139 mEq/l, according to Umemura et al (45 vs 65%). [23]

We observed that mean direct bilirubin, alanine transaminase, aspartate transaminase and alkaline phosphatase were significantly higher among group A patients as compared to those from group B or C respectively. In similar research, Meganathan et colleagues found that ALT, AST, and ALP were not substantially related to serum sodium levels. [24] Elkady et al [21] also found no correlation between ALP, AST, AST, and bilirubin and hyponatremia. Umemura et al [23] colleagues discovered that individuals with serum sodium levels of 139 mEq/l had considerably reduced median AST, ALT, GGT, and total bilirubin. We observed that mean MELD score was significantly higher among group A patients as compared to those with group B and group C. We also observed that mean Child Pugh score was significantly higher among group A patients as compared to those with group B and group C. In another study, Umemura et al [23] colleagues found that patients with MELD values of 139 mEq/l had considerably lower median MELD scores. Jenq et al [25] on the other hand, found no significant relationship between MELD score and blood sodium level. It was 32.9±13.9 for patients with sodium levels less

than 135 mEq/l and 29.4 \pm 13.6 for patients with sodium levels greater than 135 mEq/l, p=0.158. CPS was considerably higher in individuals with blood sodium levels less than 135 mEq/l (12.4 \pm 2.3) than in those with serum sodium levels greater than 135 mEq/l (11.1 \pm 2.1).

Conclusion

In conclusion, individuals with lower serum salt levels had a substantially higher MELD score and Furthermore, hepatic CPS. encephalopathy, hepatorenal syndrome, and coagulopathy were shown to be considerably more prevalent in individuals with blood sodium levels more than 130 mEq/l than in other patients. Our findings show that hyponatremia is common in people with chronic liver disease. Low blood sodium levels were linked to more severe liver disease, greater complications, and increased death. As a result, we urge that serum salt levels be checked on a frequent basis in patients with chronic liver disease. Those suffering from hyponatremia should be prioritised for acute treatment.

References

- 1. Bennani SL, Abouqal R, Zeggwagh AA, Madani N, Abidi K, Zekraoui A, Kerkeb O. Incidence, causes and prognostic factors of hyponatremia in intensive care. The Journal of Internal Medicine. 2003 Apr 1;24(4):224-9.
- Funk GC, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, Metnitz PG. Incidence and prognosis of dysnatremias present on ICU admission. Intensive care medicine. 2010 Feb; 36:304-11.
- Lindner G, Funk GC, Schwarz C, Kneidinger N, Kaider A, Schneeweiss B, Kramer L, Druml W. Hypernatremia in the critically ill is an independent risk factor for mortality. American Journal of Kidney Diseases. 2007 Dec 1;50(6):952-7.
- 4. Sedlacek M, Schoolwerth AC, and Remillard BD (2006): Electrolyte disturbances in the intensive care unit. Semin Dial, 19, 496-501.
- Zilberberg MD, Exuzides A, Spalding J, Foreman A, Graves Jones A, Colby C, Shorr AF. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Current medical research and opinion. 2008 Jun 1;24(6):1601-8.
- Kumar S, Berl T. Sodium. The Lancet. 1998 Jul 18;352(9123):220-8.
- 7. HJ A. Madias NE. Hyponatremia N Engl J Med. 2000;342(21):1581-9.
- Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrology Dialysis Transplantation. 2006 Jan 1;21(1):70-6.

- Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998 Sep;28(3):851-64.
- Attar B. Approach to Hyponatremia in Cirrhosis. Clin Liver Dis (Hoboken). 2019 Apr 30;13(4):98-101.
- John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol. 2015 Mar 21;21(11):3 197-205.
- Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology. 2008 Sep;48(3):1002-10.
- Propst A, Propst T, Zangerl G, Ofner D, Judmaier G, Vogel W. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci. 1995;40(8):1805-15.
- James K S. India's demographic change: opportunities and challenges. Science. 2011;333(6042):576-80.
- 15. Prasanna Kumari K, Udayamma KP. Prevalence of Hyponatremia among patients admitted with Cirrhosis Liver and its Correlation with Hepatic Encephalopathy. 20015;1-2.
- 16. Child CG. Surgery and portal hypertension. The liver and portal hypertension. 1964:50-2.
- 17. Rose B, Post T. Clinical physiology of acidbase and electrolyte disorders (clinical physiology of acid base & electrolyte disorders). 5th Edition: McGraw-Hill Education. 2001:2001.
- Peruzzo M, Milani GP, Garzoni L, Longoni L, Simonetti GD, Bettinelli A, Fossali EF, Bianchetti MG. Body fluids and salt metabolism-part II. Italian journal of pediatrics. 2010 Dec; 36:1-8.
- Kumar S, Berl T. Sodium. The Lancet. 1998 Jul 18 ;352(9123):220-8.
- 20. Madias NE, Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21) :1581-9.
- 21. Elkady MS, El-Toukhy NE, Rashed SE. Serum Sodium Concentration Profile in Cirrhotic Patients and its Effect on the Prognostic Value of the MELD Score. SAS J. Surg. 2016;2(6) :266-77.
- 22. Kim JH, Lee JS, Lee SH, Bae WK, Kim NH, Kim KA, Moon YS. The association between the serum sodium level and the severity of complications in liver cirrhosis. The Korean journal of internal medicine. 2009 Jun 8;24(2): 106-12.
- 23. Umemura T, Shibata S, Sekiguchi T, Kitabatake H, Nozawa Y, Okuhara S, Kimura T, Morita S, Komatsu M, Matsumoto A, Tanaka E. Serum sodium concentration is associated with increased risk of mortality in

patients with compensated liver cirrhosis. Hepatology Research. 2015 Jul;45(7):739-44.

- 24. Meganathan A, Kumar VS. Hyponatremia in cirrhosis- prevalence and correlation with the complications of cirrhosis. J Evol Med Dental Sci. 2018;7(18):2197-202.
- 25. Jenq CC, Tsai MH, Tian YC, Chang MY, Lin CY, Lien JM, Chen YC, Fang JT, Chen PC, Yang CW. Serum sodium predicts prognosis in critically ill cirrhotic patients. Journal of clinical gastroenterology. 2010 Mar 1;44(3): 220-6.